These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 7533226)

  • 1. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP; Christen MO
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why imidazoline receptor modulator in the treatment of hypertension?
    Schäfer SG; Kaan EC; Christen MO; Löw-Kröger A; Mest HJ; Molderings GJ
    Ann N Y Acad Sci; 1995 Jul; 763():659-72. PubMed ID: 7677385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of moxonidine, an I1-imidazoline receptor agonist.
    Ziegler D; Haxhiu MA; Kaan EC; Papp JG; Ernsberger P
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S26-37. PubMed ID: 8872297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.
    Prichard BN; Graham BR
    Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine.
    Van Zwieten PA; Peters SL
    Ann N Y Acad Sci; 1999 Jun; 881():420-9. PubMed ID: 10415946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist.
    Ernsberger P; Haxhiu MA; Graff LM; Collins LA; Dreshaj I; Grove DL; Graves ME; Schäfer SG; Christen MO
    Cardiovasc Drugs Ther; 1994 Mar; 8 Suppl 1():27-41. PubMed ID: 8068578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives.
    Wenzel RR; Spieker L; Qui S; Shaw S; Lüscher TF; Noll G
    Hypertension; 1998 Dec; 32(6):1022-7. PubMed ID: 9856967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of moxonidine in the treatment of hypertension.
    Prichard BN; Graham BR
    J Hypertens Suppl; 1997 Jan; 15(1):S47-55. PubMed ID: 9050986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension?
    van Zwieten PA
    Am J Cardiovasc Drugs; 2001; 1(5):321-6. PubMed ID: 14728014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla.
    Haxhiu MA; Dreshaj I; Schäfer SG; Ernsberger P
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S1-8. PubMed ID: 7533221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.
    Ernsberger P; Friedman JE; Koletsky RJ
    J Hypertens Suppl; 1997 Jan; 15(1):S9-23. PubMed ID: 9050981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of the imidazoline receptor agonist moxonidine on hemodynamics, coronary circulation, metabolic ischemia markers and the neurohumoral system in patients with essential hypertension. Effects of moxonidine on coronary circulation].
    Mitrovic V; Hamel M; Miric M; Thormann J; Hamm C
    Z Kardiol; 2001 Dec; 90(12):953-63. PubMed ID: 11826837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug withdrawal and rebound hypertension: differential action of the central antihypertensive drugs moxonidine and clonidine.
    Rupp H; Maisch B; Brilla CG
    Cardiovasc Drugs Ther; 1996 Jun; 10 Suppl 1():251-62. PubMed ID: 8827948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxonidine: a new and versatile antihypertensive.
    Messerli F
    J Cardiovasc Pharmacol; 2000; 35(7 Suppl 4):S53-6. PubMed ID: 11346219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From alpha and beta to I1: an overview of sympathetic receptors involved in blood pressure control targets for drug treatment.
    van Zwieten PA
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S5-10. PubMed ID: 8872294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension.
    Küppers HE; Jäger BA; Luszick JH; Gräve MA; Hughes PR; Kaan EC
    J Hypertens; 1997 Jan; 15(1):93-7. PubMed ID: 9050976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moxonidine: a review of safety and tolerability after seven years of clinical experience.
    Schachter M
    J Hypertens Suppl; 1999 Aug; 17(3):S37-9. PubMed ID: 10489097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.